Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Some preclinical in vivo studies and limited human data suggest a possible increased risk of bladder cancer with pioglitazone therapy. This is an interim report of an ongoing cohort study examining the association between pioglitazone therapy and the risk of bladder cancer in patients with diabetes. RESEARCH DESIGN AND METHODS: This study includes 193,099 patients in the Kaiser Permanente Northern California diabetes registry who were ≥40 years of age between 1997 and 2002. Those with prior bladder cancer were excluded. Ever use of each diabetes medication (defined as two or more prescriptions within 6 months) was treated as a time-dependent variable. Cox regression–generated hazard ratios (HRs) compared pioglitazone use with nonpioglitazone use adjusted for age, sex, race/ethnicity, diabetes medications, A1C, heart failure, household income, renal function, other bladder conditions, and smoking. RESULTS: The group treated with pioglitazone comprised 30,173 patients. There were 90 cases of bladder cancer among pioglitazone users and 791 cases of bladder cancer among nonpioglitazone users. Overall, ever use of pioglitazone was not associated with risk of bladder cancer (HR 1.2 [95% CI 0.9–1.5]), with similar results in men and women (test for interaction P = 0.8). However, in the a priori category of >24 months of therapy, there was an increased risk (1.4 [1.03–2.0]). Ninety-five percent of cancers diagnosed among pioglitazone users were detected at early stage. CONCLUSIONS: In this cohort of patients with diabetes, short-term use of pioglitazone was not associated with an increased incidence of bladder cancer, but use for more than 2 years was weakly associated with increased risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Observational research conducted in 2011 and 2012 suggested that pioglitazone may increase the risk of bladder cancer.46,47”
From Pioglitazone after Ischemic Stroke or Transient Ischemic Attack (2016) · cites this paper as [46]
The cited source says what the claim attributes to it.
In the citing paper
“Of note, some data suggest an association between the use of pioglitazone and an increased risk of bladder cancer (191).”
From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [191]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124 · cited 1×
“Some research suggests that metformin use is associated with a reduced risk for various cancers (23,24); others have suggested that insulin use might increase the risk of cancer (24,25).”
BackgroundDiabetes and Cancer: A Consensus Report
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20078 · Cited by 1,055
Elstner, E., Müller, C., Koshizuka, K., Williamson, E. A., Park, D., Asou, H., Shintaku, P., Said, J. W., Heber, D., & Koeffler, H. P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8806 · Cited by 805
Tontonoz, P., Singer, S., Forman, B. M., Sarraf, P., Fletcher, J. A., Fletcher, C. D. M., Brun, R. P., Mueller, E., Altiok, S., Oppenheim, H., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.1.237 · Cited by 653
Kubota, T., Koshizuka, K., Williamson, E. A., Asou, H., SAID, J. W., Holden, S. A., Miyoshi, I., & Koeffler, H. P. (1998) · PubMed · Cited by 589
Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes
Govindarajan, R., Ratnasinghe, L., Simmons, D. L., Siegel, E. R., Midathada, M. V., Kim, L., Kim, P. J., Owens, R. J., & Lang, N. P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.2777 · Cited by 336
Cited by
Items 501–600 of 711
Diabetes Mellitus and Peripheral Vascular Disease
Freeby, M. (2012) · Humana Press eBooks · doi:10.1007/978-1-62703-158-5_3 · Cited by 3
Pioglitazone for the treatment of type 2 diabetes
Nabrdalik, K., Cichocka, E., Żywiec, J., Chodkowski, A., & Gumprecht, J. (2014) · Clinical Diabetology · Cited by 3
García-Vallvé, S., Guasch, L., & Mulero, M. (2014) · Springer eBooks · doi:10.1007/978-3-319-10226-9_6 · Cited by 3
Li, S., & Tian, H. (2013) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2013.37.1.81 · Cited by 3
Yang, X., & Weng, J. (2012) · Journal of Diabetes Investigation · doi:10.1111/jdi.12020 · Cited by 3
The Management of Type 2 Diabetic Patients with Hypoglycemic Agents
Schianca, G. P. C., Sola, D., Rossi, L. C., Fra, G. P., & Bartoli, E. (2012) · ISRN Endocrinology · doi:10.5402/2012/601380 · Cited by 3
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M. A., Peters, A. L., Τσάπας, Α., Wender, R. C., & Matthews, D. R. (2012) · Cited by 3
Pioglitazone: No Longer a Worry for Bladder Cancer?
Chedgy, E. C. P., & Black, P. C. (2016) · Urology · doi:10.1016/j.urology.2016.01.015 · Cited by 3
Vallabhajosyula, S., Vallabhajosyula, S., Vallabhajosyula, S., Nair, S., Kamath, A., & Rao, K. N. (2016) · Medical Journal Armed Forces India · doi:10.1016/j.mjafi.2016.06.004 · Cited by 3
Update on Pharmacotherapy for Type 2 Diabetes
Ahmed, S. S., Ali, M. Z., Laila, T. R., Begum, H. A., & Ali, T. M. M. (2013) · KYAMC Journal · doi:10.3329/kyamcj.v3i1.13661 · Cited by 3
Zhuo, L., Xu, J., You, N., Wang, L., Song, Y., Luo, Y., & Shi, J. (2020) · Medicine · doi:10.1097/md.0000000000022867 · Cited by 3
Banyumas, P. Y., Utomo, C. S., Julianto, E. N., Banyumas, P. Y., Puspasari, F. D., & Banyumas, P. Y. (2020) · Journal of Nursing and Health · doi:10.52488/jnh.v5i2.121 · Cited by 3
Thiazolidinediones/insulin use and cancer risk: Insights from the recent meta-analyses
Simon, D. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.01.001 · Cited by 3
Journals, I., & Santhosh Kumar, M. (2014) · Figshare · doi:10.6084/m9.figshare.1278828 · Cited by 3
Pioglitazone Use and Risk of Bladder Cancer—Reply
Ferrara, A. M., Lewis, J. D., & Habel, L. A. (2015) · JAMA · doi:10.1001/jama.2015.13915 · Cited by 3
Self-citationMilton, F. A. (2015) · RIUnB Institutional Repository (University of Brasília) · doi:10.26512/2015.02.t.18077 · Cited by 3
Kodani, E. (2016) · Circulation Journal · doi:10.1253/circj.cj-16-1185 · Cited by 3
SGLT2 inhibitor and urothelial carcinoma incidence in type 2 diabetes patients
Lu, Y.-C., Chang, C., Ho, C., Hong, J., Yeh, H.-M., Chang, Y., Hsiao, P.-J., Lien, C., Wu, L.-Y., & Chung, C. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101694 · Cited by 2
Archana, P., Kumar, T. D. A., Ganesh, N. V., Mohammed, M., Tavanoji, H. P., Deepikarani, R., & Kumar, B. R. P. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118393 · Cited by 2
Nutzen und Risiken der modernen Pharmakotherapie des Typ-2-Diabetes
Schindler, C., Barthel, A., Fischer, S., Bornstein, S. R., & Kirch, W. (2012) · Der Internist · doi:10.1007/s00108-012-3014-9 · Cited by 2
Role of Insulin-Sensitizing Drugs in PCOS Management
Awwad, J. T., & Ghazeeri, G. S. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8394-6_10 · Cited by 2
Pioglitazone Induced Carcinoma of Urinary Bladder: A Case Report
Takalkar, U. V., Asegaonkar, S. B., & Advani, S. H. (2013) · HAL · Cited by 2
NEW IN THE TREATMENT OF TYPE 2 DIABETES
Kadzharyan, V. G., & Kapshytar, N. I. (2014) · Zaporozhye Medical Journal · doi:10.14739/2310-1210.2014.1.23806 · Cited by 2
Katsuyama, H., Fukunaga, T., Hamasaki, H., Adachi, H., Moriyama, S., Kawaguchi, A., Mishima, S., Sako, A., & Yanai, H. (2016) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2611w · Cited by 2
Bage, I. J., Kamalanathan, S., Selvarajan, S., Sahoo, J., Mathaiyan, J., & Naik, D. (2023) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20231121 · Cited by 2
Diabetes and Cancer: Evidence for Risk, Methodology and Implications
Badrick, E., & Renehan, A. G. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch54 · Cited by 2
Haq, M. E. U., Akash, M. S. H., Rehman, K., & Khurshid, M. (2020) · Turkish Journal of Biochemistry · doi:10.1515/tjb-2019-0318 · Cited by 2
Maximizing treatment benefits in type 2 diabetes by affordable oral anti diabetes agents in India
Das, A. K., Krishnakumar, B., Ajish, T., Sheohare, R., & Chittawar, S. (2021) · International Journal of Advances in Medicine · doi:10.18203/2349-3933.ijam20213722 · Cited by 2
Dinda, B., & Saha, S. (2022) · Springer eBooks · doi:10.1007/978-3-030-92196-5_1 · Cited by 2
Chen, L., Xu, T., Wang, J., Wang, Z., Pan, Y., & Kong, L. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118878 · Cited by 2
Nb, G., Rajesh, D., & Muppala, T. (2015) · International Journal of Pharmacy and Pharmaceutical Sciences · Cited by 2
What Have We Learned About the Treatment of Type 2 Diabetes? The Evolving Paradigms
Freeman, J. S., & Horton, E. S. (2012) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31826fc5e5 · Cited by 2
Zhao, Q., & Marcy, T. R. (2013) · The Consultant Pharmacist · doi:10.4140/tcp.n.2013.515 · Cited by 2
Jin, S., Oh, B. J., Lee, S., Choi, J. M., Yang, S. J., Park, S. W., Kim, K., Kim, J. H., & Park, C. (2013) · Yonsei Medical Journal · doi:10.3349/ymj.2013.54.5.1127 · Cited by 2
Use of noninsulin anti diabetics for prevention and treatment of cancer- narrative review article.
Raana, S., & Javeed, A. (2015) · PubMed Central · Cited by 2
Emerging Link between Diabetes and Cancer
Noto, H., Goto, A., Tsujimoto, T., & Noda, M. (2015) · Journal of General and Family Medicine · doi:10.14442/jgfm.16.3_170 · Cited by 2
α-Glukosidase-Hemmer und Thiazolidindione (Glitazone): Kardiovaskuläre Effekte
Scherbaum, W. A. (2016) · Der Diabetologe · doi:10.1007/s11428-016-0085-6 · Cited by 2
(SFD), U. P. D. P. P. P. L. S. F. D. D. (2012) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(12)70660-0 · Cited by 2
Polemics of pioglitazone: an appraisal in 2015
Singh, A. K. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.1054809 · Cited by 2
L’internista ospedaliero nella gestione del paziente diabetico complesso
Magnani, G. E. L., Beltramello, G., Brancato, D., Fontanella, A., & Nardi, R. (2018) · Italian Journal of Medicine · doi:10.4081/itjm.q.2018.2 · Cited by 2
Hillson, R. (2018) · Practical Diabetes · doi:10.1002/pdi.2167 · Cited by 2
Functional network analysis of gene‑phenotype connectivity based on pioglitazone
Wang, W., Zhang, L., Wang, X., Lin, D., Pan, Q., & Guo, L. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.8162 · Cited by 2
Antidiabetic drugs and the risk of cancer: beneficial, neutral, or detrimental?
Azeez, T. A., Folorunso, S. A., Eguzozie, C., & Adegboyega, A. A. (2021) · Forum of Clinical Oncology · doi:10.2478/fco-2021-0014 · Cited by 2
Jackson, B. L., Griffiths, T. R. L., & Mellon, J. K. (2014) · Springer eBooks · doi:10.1007/978-0-85729-482-1_31 · Cited by 2
Fontanarosa, P., Bauchner, H., & Golub, R. M. (2015) · JAMA · doi:10.1001/jama.2015.8232 · Cited by 2
Closing sale of innovative treatment options for the treatment of diabetes and metabolic disorders?
Schindler, C. (2011) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018811430839 · Cited by 2
Davidson, M. (2018) · uO Research (University of Ottawa) · doi:10.20381/ruor-22317 · Cited by 2
Die Interaktion des Kernrezeptors PPARγ mit der Lipidphosphatase MTMR7 im kolorektalen Karzinom
Weidner, P. (2018) · heiDOK (Heidelberg University) · doi:10.11588/heidok.00023843 · Cited by 2
Pioglitazone Induces Dysplastic Urothelial Changes in Urinary Bladder of Experimental Diabetes
Abdel‐Hamid, A. A. M., & Firgany, A. E. D. (2021) · Journal of Microscopy and Ultrastructure · doi:10.4103/jmau.jmau_34_21 · Cited by 1
Badrick, E., Gallagher, E. J., & Renehan, A. G. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch60 · Cited by 1
Synthesis, in vitro and in vivo Antidiabetic Activity of N-Substituted Thiazolidinedione Derivatives
Jain, U. N., Jain, N. P., & Amrutkar, S. V. (2025) · Asian Journal of Chemistry · doi:10.14233/ajchem.2025.34125 · Cited by 1
An Overview of Diabetes and Cancer Risks: Types and Mechanisms
Muruganantham, J. K., & Veerabathiran, R. (2026) · Springer eBooks · doi:10.1007/978-981-95-5651-9_1 · Cited by 1
The prognosis of patients with coronary artery disease complicated by postload hyperinsulinemia
Yamasa, T., Ikeda, S., Koga, S., Nakatomi, D., Mutoh, S., Sonoda, K., Hata, S., & Maemura, K. (2014) · IJC Metabolic & Endocrine · doi:10.1016/j.ijcme.2014.07.008 · Cited by 1
Pharmacothérapie du diabète de type 2
Harper, W., CLEMENT, M. A., Goldenberg, R., Hanna, A., Main, A., Retnakaran, R. R., Sherifali, D., Woo, V. C., & Yale, J. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.07.006 · Cited by 1
Non-Insulin Agents for Diabetes
Sreemantula, G., & Shankarnarayan, S. H. (2012) · doi:10.1007/978-1-908517-81-4_4 · Cited by 1
Dong, Y., & WANG, A. (2016) · Oncology Letters · doi:10.3892/ol.2016.4566 · Cited by 1
Robertson, C. L., Sarkar, D., & Sanyal, A. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-34214-6_18 · Cited by 1
Kubota, K. (2012) · Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics · doi:10.3999/jscpt.43.1 · Cited by 1
Monnier, L., Colette, C., & Wojtusciszyn, A. (2011) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(11)70329-7 · Cited by 1
Horita, S., Nakamura, M., Suzuki, M., Yamada, H., & Seki, G. (2013) · Open Journal of Endocrine and Metabolic Diseases · doi:10.4236/ojemd.2013.35a003 · Cited by 1
Traitement du diabète et cancer : enquête à propos de deux controverses
Simon, D. (2014) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(14)70834-x · Cited by 1
Çağıltay, E., Tunçel, T., Yönem, A., & Ozdemir, G. (2012) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2012.12.002 · Cited by 1
Medjakovic, S. (2014) · Natural Products Chemistry & Research · doi:10.4172/2329-6836.1000136 · Cited by 1
The ‘collateral benefits‘ of noninsulin therapies for Type 2 diabetes
Roe, E. D., PON, N. C., Hollander, P. A., & Raskin, P. (2013) · Diabetes Management · doi:10.2217/dmt.13.5 · Cited by 1
Kalra, S., Unnikrishnan, A., & Bantwal, G. (2011) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.83048 · Cited by 1
Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease
Park, S. H. (2014) · Korean Journal of Medicine · doi:10.3904/kjm.2014.86.4.425 · Cited by 1
Pioglitazone: lessons and learnings 15 years since launch and beyond
Stempa, O. (2015) · Diabetes Management · doi:10.2217/dmt.15.38 · Cited by 1
Review of current and potential future pharmacological treatments in nonalcoholic steatohepatitis
Akhter, A., Pulla, A., & Said, A. (2016) · Clinical Liver Disease · doi:10.1002/cld.523 · Cited by 1
Giri, B., Sarkar, M., & Dey, S. (2017) · Journal of Stem Cell and Regenerative Biology · doi:10.15436/2471-0598.16.017 · Cited by 1
Tourkmani, A. M., Alharbi, T., Abdelhay, O., Alkhashan, H. I., Obaikan, A. A., Alaboud, A. F., Bakhiet, A., Alqahtani, H., Battal, S. A., & Abanami, N. (2017) · Clinical Audit · doi:10.2147/ca.s122952 · Cited by 1
Noto, H. (2017) · Springer eBooks · doi:10.1007/978-981-10-4376-5_9 · Cited by 1
Hans, N. (2020) · International Journal of Medical Science and Diagnosis Research · Cited by 1
Fetene, G., Ambachew, S., Fasil, A., & Abebe, M. (2020) · Pharmacy & Pharmacology International Journal · doi:10.15406/ppij.2020.08.00287 · Cited by 1
Management of type 2 diabetes without insulin: An update for the PCP
Thiruvengadam, S., & Peter, P. R. (2021) · Disease-a-Month · doi:10.1016/j.disamonth.2021.101290 · Cited by 1
Ausdauer- und Krafttraining bei Patienten mit Diabetes mellitus Typ 2 und Herzinsuffizienz
Niederseer, D., & Niebauer, J. (2012) · Herz · doi:10.1007/s00059-012-3635-8 · Cited by 1
Role of Insulin-Sensitizing Drugs in PCOS Management
Kojok, D., Ghazeeri, G. S., & Awwad, J. T. (2022) · Springer eBooks · doi:10.1007/978-3-030-92589-5_12 · Cited by 1
Desai, N. S., & Mirmirani, P. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54825-0.00012-0 · Cited by 1
Overview of North American Databases
Strom, B. L., Schinnar, R., & Kinman, J. L. (2014) · Wiley eBooks · doi:10.1002/9781118820186.ch25 · Cited by 1
Self-citationDalal, D., Jain, P., & Puthenpurayil, S. J. (2024) · International Journal of Health Sciences and Research · doi:10.52403/ijhsr.20240208 · Cited by 1
Che Roos, N. A. (2019) · Enlighten: Theses (The University of Glasgow) · doi:10.5525/gla.thesis.41064 · Cited by 1
Liječenje nealkoholne masne bolesti jetre
Mikolašević, I., Milić, S., Orlić, L., Stanić, M., Štimac, D., Mavrinac, V., & Vlahović-Palčevski, V. (2016) · University of Zagreb University Computing Centre (SRCE) · Cited by 1
Dedicated to evidence-based medicine and the evaluation of new therapeutic approaches in the field
Schindler, C. (2011) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018811417971 · Cited by 1
Mesquita, P. G. (2015) · RIUnB Institutional Repository (University of Brasília) · doi:10.26512/2015.08.t.19730 · Cited by 1
Diabetes therapy and cancer risk (October 2014)
Weiß, D. (2014) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.81c.12001 · Cited by 1
Carroll, R. W. (2017) · Otago University Research Archive (University of Otago) · Cited by 1
Evolución de la atención a la Diabetes tipo 2 en Catalunya 1993-2013
Mata‐Cases, M. (2017) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) · Cited by 1
Schrijnders, D. (2019) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.103517830 · Cited by 1
In Reply: Diabetes therapy and cancer risk (October 2014)
Sun, G. E. C., Kashyap, S. R., & Nasr, C. E. (2014) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.81c.12002 · Cited by 1
Öğrencilerin çağdaş resim sanatını öğrenmelerinde yeniden üretilen yapıtların etkileri
Girgin, F. (2015) · Marmara University Open Access System · Cited by 1
Mecanismos patológicos e prevenção farmacológica da carcinogénese urotelial: estudo experimental
Parada, B. (2014) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 1
Moosecker, S. (2019) · mediaTUM (Technical University of Munich) · Cited by 1
Rabah, B., & Bahbah, L. (2016) · Dépôt Institutionnel de lUniversité de Tlemcen · Cited by 1
Shi, M. (2019) · theses.fr (ABES) · doi:10.70675/3635da7az5e15z4aaaz890cz02e6ace799ec · Cited by 1
Identification et validation de cibles thérapeutiques pour traiter le syndrome de Wolfram
Crouzier, L. (2022) · theses.fr (ABES) · doi:10.70675/08925254zdf40z489azbca7z0368a13932ef · Cited by 1
Faillie, J. (2014) · Thèses en ligne de l'Université Toulouse III (Université Toulouse III)
Diabetes Mellitus Prevention and Treatment
Dunn, A. V., & Nyalakonda, K. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-380-0_5
PHARMACOTHERAPY OF PIOGLITAZONE AND ITS CURRENT STATUS IN INDIA
Tamma, N. K. (2013) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v3i5.602
Epidemiology and Natural History
Messing, E. M., & Scosyrev, E. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1881-2_1
Metadata
- Authors
- Lewis, J. D., Ferrara, A., Peng, T., Hedderson, M., Bilker, W. B., Quesenberry, C. P., Vaughn, D. J., Nessel, L., Selby, J., & Strom, B. L.
- Affiliations
- University of Pennsylvania (US)
- Kaiser Permanente (US)
- Corresponding author
- Lewis, James D.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2011-03-21
- Volume
- 34
- Issue
- 4
- Pages
- 916-922
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3064051
- OpenAlex
- W2121264929
- Cited by
- 625
- References
- 24
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 10 · 2023: 10 · 2022: 19 · 2021: 18 · 2020: 25 · 2019: 21 · 2018: 29 · 2017: 35 · 2016: 55 · 2015: 58 · 2014: 79 · 2013: 90 · 2012: 119
- FWCI
- 42.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- pioglitazone, bladder cancer, diabetes mellitus, drug safety, cancer risk, treatment duration, thiazolidinediones, antidiabetic drugs, early-stage cancer detection
- MeSH terms
- Pioglitazone, Adult, Aged, Urinary Bladder Neoplasms, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Longitudinal Studies, Male, Middle Aged, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.